Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.

Leukemia & lymphoma - 1 Sept 2023

Patel Shyam A

Abstract excerpt

The year 2023 marks the semi-centennial of the introduction of classic '7 + 3' chemotherapy for acute myeloid leukemia (AML) in 1973. It also marks the decennial of the first comprehensive sequencing efforts from The Cancer Genome Atlas (TCGA), which revealed that dozens of unique genes are recurrently mutated in AML genomes. Although more than 30 distinct genes have been implicated in AML pathogenesis, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation
Share to Nucleophosmin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 37328939
DOI: 10.1080/10428194.2023.2224473
PMCID: PMC10913147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.PMID 37328939Read ↗

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.Semantic proximity Read ↗

How to improve AML outcomes?Semantic proximity Read ↗

Defining and managing high-risk acute myeloid leukemia (AML) in 2026.Semantic proximity Read ↗

How I treat AML incorporating the updated classifications and guidelines.Semantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

A precision medicine classification for treatment of acute myeloid leukemia in older patients.Semantic proximity Read ↗

Towards precision medicine for AML.Semantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

Contemporary Management of Acute Myeloid Leukemia: A Review.Semantic proximity Read ↗

Precision medicine in AML: overcoming resistance.Semantic proximity Read ↗

Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomesSemantic proximity Read ↗

Biomarkers and advances in AML-MRC: from bench to bedside.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.